Krabbe-Disease Medical Cannabis Studies

Cannabinoids inhibit neurodegeneration in models of multiple sclerosis (2003)

The therapeutic use of cannabis could alleviate symptoms and delay neurodegenerative processes in multiple sclerosis and other diseases. View study
Experimental autoimmune encephalomyelitis disrupts endocannabinoid-mediated neuroprotection (2005)

Through experimental methods, these studies suggest the potential of cannabinoids in the development of neuroprotective drugs for the treatment of multiple sclerosis. View study
The Endocannabinoid System Is Dysregulated in Multiple Sclerosis and in Experimental Autoimmune Encephalomyelitis (2016)

The ability of cannabinoids to modulate both neuronal inflammatory and degenerative damage led to investigations into the potential benefits of such compounds in multiple sclerosis (MS) and in animal models of this disorder. The present study focused on measuring endocannabinoid levels, metabolism and binding, and physiological activities in 26 patients with MS View study
Therapeutic Action of Cannabinoids in a Murine Model of Multiple Sclerosis (2003)

Theiler’s virus infection of the CNS induces an immune-mediated demyelinating disease in susceptible mouse strains and serves as a relevant infection model for human multiple sclerosis (MS). The objective of the present research was to study the therapeutic action of cannabinoids in a murine model of multiple sclerosis. By using Theiler’s murine encephalomyelitis virus model, we report here that the treatment with the synthetic cannabinoids WIN 55,212-2, ACEA and JWH-015 during the established disease significantly improved the neurological deficits in a lasting manner. View study